2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
04:30 p.m. - 06:00 p.m.
MCCNO - Hall C
This session are outstanding clinical trials in ET and PV. Suggested session title<br /><br /><span style="caret-color: #000000; color: #000000; font-family: Aptos, Aptos_EmbeddedFont, Aptos_MSFontService, Calibri, Helvetica, sans-serif; font-size: 14.666667px; font-style: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration: none; display: inline !important; float: none;">ET and PV: Moving Beyond Conventional Therapy</span>
Treatment Considerations, Drug Development, Biological Therapies, Antibody Therapy, Bispecific Antibody Therapy, Adverse Events, Biological Processes, Genomics, Hematopoiesis, Immune Mechanism, Clinical Practice (Health Services and Quality), Diseases, Bleeding and Clotting, Bleeding Disorders, Platelet Disorders, Thromboembolism, Thrombotic Disorders, VWD, Myeloid Malignancies, Chronic Myeloid Malignancies, Research, Translational Research, MDS, MPN, CMML, Clinical Research, Clinical Trials, Study Population, Human, Adult, Elderly, Young Adult
PAPER

1035 Clinical and molecular factors associated with sustained treatment-free remission following ropeginterferon alfa-2b discontinuation in polycythemia vera: Interim Results from the prospective multicenter study (FiRM-PV)

Sung-Eun Lee, MD, PhD, Junshik Hong, MD2, Deok-Hwan Yang, MD3, Gyeong-Won Lee4, Seug Yun Yoon, MD, PhD5, Sang Kyun Sohn6, Ho-Jin Shin, MD7, Sung Hwa Bae, MD8, Chul Won Choi9, Yunsuk Medical Choi, MD, PhD10, June-won Cheong, MD, PhD11, Soo-Mee Bang, MD, PhD12, Jong Wook Lee13
1 Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea, Rep. of South
2 Seoul National University College of Medicine, Seoul, Korea, Rep. of South
3 Chonnam National University Hwasun Hospital, Chonnam National University Medical School, Jeollanam-do, Korea, Rep. of South
4 Gyeongsang National University Hospital, Gyeongsang National University College of Medicine, Jinju, Korea, Rep. of South
5 Soonchunhyang University Seoul Hospital, Seoul, Korea, Rep. of South
6 Kyungpook National University Hospital, Daegu, Korea, Rep. of South
7 Pusan National University Hospital, Pusan, Korea, Rep. of South
8 Daegu Catholic, University Hospital, Daegu Catholic University School of Medicine, Daegu, Korea, Rep. of South
9 Korea University Medical Center, Seoul, Korea, Rep. of South
10 Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea, Rep. of South
11 Severance Hospital, Yonsei University College of Medicine, Seoul, Korea, Rep. of South
12 Seoul National University College of Medicine, Seoul National University Bundang Hospital, Seongnam, Korea, Rep. of South
13 Hanyang University Medical Center Seoul, Seoul, Korea, Rep. of South
Background

Interferon (IFN) may induce treatment-free remission (TFR) after discontinuation in patients with polycythemia vera (PV). Long-term treatment with Ropeginterferon alfa-2b (Ropeg) induces durable complete hematologic response (CHR) and progressive JAK2V617F reduction, suggesting disease-modifying potential. However, no prospective study has evaluated whether the disease-modifying effects of Ropeg translate into sustained TFR after treatment discontinuation, and the clinical and molecular factors associated with successful treatment discontinuation remain unknown. Therefore, this prospective study evaluated the feasibility of Ropeg discontinuation and identified the clinical and molecular factors associated with sustained TFR.

Methods

This prospective multicenter investigator-initiated study enrolled patients who completed the 3-year high initial dose accelerated titration (HIDAT) regimen with Ropeg in the preceding PV IIT study (Yoon et al., 2025) and maintained CHR for ≥24 weeks immediately before treatment discontinuation. CHR was defined according to the ELN 2013 criteria. Patients were evaluated at 4 weeks after discontinuation and every 12 weeks thereafter. The primary endpoint was TFR, defined as treatment-free survival without hematologic relapse (loss of CHR on two consecutive assessments); 6- and 12-month TFR are reported. Relapsed patients were rechallenged with the Ropeg HIDAT regimen. TFR was estimated using the Kaplan–Meier method. Clinical and molecular factors associated with TFR were evaluated using Cox proportional hazards regression with backward likelihood ratio selection. ROC analysis identified clinically relevant cutoffs, and CHR re-achievement after rechallenge was assessed.

Results

As of July 1, 2026, 59 patients were enrolled, with a median follow-up of 330 days (IQR, 241–428). Median CHR duration at discontinuation was 2.75 years; the median age was 58 years, and 55.9% were hydroxyurea-naïve. During follow-up, 19 patients (32%) developed confirmed hematologic relapse. Estimated TFR rates were 80.7% at 6 months and 67.2% at 12 months, whereas median TFR was not reached.

In univariable Cox analyses, prolonged CHR duration (HR 0.28 per additional year of CHR, 95% CI 0.16–0.50; P<0.001), greater JAK2V617F reduction from pretreatment baseline (HR 0.97 per 1% greater reduction, 95% CI 0.95–0.98; P<0.001), and female sex (HR 0.11, 95% CI 0.03-0.38; p<0.001) were associated with a lower risk of relapse, whereas higher residual JAK2V617F allele burden (HR 1.03 per 1% increase, 95% CI 1.00–1.06; P=0.02) was associated with a higher risk of relapse.

In the final multivariable model including age, sex, CHR duration, and residual JAK2V617F allele burden, prolonged CHR duration (HR 0.37 per additional year, 95% CI 0.19–0.74; P=0.005) and residual JAK2V617F allele burden (HR 1.58 per 10% increase, 95% CI 1.05–2.38; P=0.030) remained independently associated with TFR. In an alternative multivariable model including age, sex, CHR duration, and JAK2V617F reduction from pretreatment baseline, greater JAK2V617F reduction remained independently associated with TFR (HR 0.74 per 10% greater reduction, 95% CI 0.58–0.95; P=0.019).

ROC analyses identified clinically relevant cutoff values of 2 years for CHR duration, ≤2% for residual JAK2V617F allele burden, and ≥98.5% for JAK2V617F reduction from pretreatment baseline, corresponding AUCs of 0.75, 0.84, and 0.85, respectively. Using these cutoffs (all log-rank p<0.001), the 6-month TFR rates were 93.2% in patients with CHR duration ≥2 years, 93.8% in those with a residual JAK2V617F allele burden ≤2%, and 100% in those with JAK2V617F reduction rate ≥98.5%. Among 19 patients with confirmed hematologic relapse, 13 were evaluable after Ropeg rechallenge, and all re-achieved CHR.

Conclusion                                                                                                      

Treatment discontinuation after long-term Ropeg resulted in durable TFR in a substantial proportion of patients with PV. Sustained hematologic response and continued reduction in JAK2V617F allele burden identified patients suitable for treatment discontinuation, beyond conventional CHR or MR. Importantly, all evaluable relapsed patients re-achieved CHR following Ropeg rechallenge. These findings support consideration of treatment discontinuation and treatment holidays in carefully selected patients with PV, with no evidence of acquired resistance to Ropeg upon retreatment.

Sung-Eun Lee, MD, PhD: PharmaEssentia - Research Funding; Bristol Myers Squibb - Consultancy (Includes expert testimony); PharmaEssentia - Consultancy (Includes expert testimony); Novartis - Consultancy (Includes expert testimony); GlaxoSmithKline - Consultancy (Includes expert testimony)